Drug Trial Radar · NCT05018806
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Sep 9, 2021
Primary completion
Jun 23, 2023
Study completion Jun 23, 2023
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18 years) with moderate-to-severe AD and intolerance or inadequate response to topical corticosteroids (TCS). The total study duration per participant was expected to be approximately 21 weeks, including up to 4 weeks of screening, 16 weeks of on-treatment double-blind period, 1 week of post-treatment follow-up.
Conditions
- Atopic Dermatitis
Interventions
PlaceboDrug
Pharmaceutical form: Tablet Route of administration: Oral
RilzabrutinibDrug
Pharmaceutical form: Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) ScoreTime frame: Baseline (Day 1) to Week 16
Locations
31 sites in 7 countries. Site status is shown where the registry gives one.
Antelope Valley Clinical Trials Site Number : 8400001
Northridge, California
Asthma and Allergy Associates, PC Site Number : 8400008
Colorado Springs, Colorado
Florida International Research Center Site Number : 8400002
Miami, Florida
Skin Sciences, PLLC Site Number : 8400005
Louisville, Kentucky
DS Research of Kentucky, LLC Site Number : 8400004
Louisville, Kentucky
Integrative Skin Care of MS/SKYCRNG Site Number : 8400011
Ridgeland, Mississippi
National Allergy and Asthma Research, LLC. Site Number : 8400007
North Charleston, South Carolina
Orion Clinical Research Site Number : 8400003
Austin, Texas
E.P.I.M.R.D dba Western Sky Research, Inc. Site Number : 8400009
El Paso, Texas
Investigational Site Number : 1240004
Québec, Canada
Investigational Site Number : 1240008
Red Deer, Alberta, Canada
Investigational Site Number : 1240013
Greater Sudbury, Ontario, Canada
Investigational Site Number : 1240001
London, Ontario, Canada
Investigational Site Number : 1240002
Markham, Ontario, Canada
Investigational Site Number : 1240011
Toronto, Ontario, Canada
Investigational Site Number : 1240007
Toronto, Ontario, Canada
Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 2030004
Olomouc, Czechia
Investigational Site Number : 2030003
Pardubice, Czechia
Investigational Site Number : 2030002
Pilsen, Czechia
Investigational Site Number : 2030001
Prague, Czechia
Investigational Site Number : 2760001
Bad Bentheim, Germany
Investigational Site Number : 2760002
Friedrichshafen, Germany
Investigational Site Number : 5280001
Utrecht, Netherlands
Investigational Site Number : 6160008
Chojnice, Poland
Investigational Site Number : 6160002
Lodz, Poland
Investigational Site Number : 6160004
Warsaw, Poland
Investigational Site Number : 6160001
Lodz, Lódzkie, Poland
Investigational Site Number : 6160005
Gdansk, Pomeranian Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.